Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment
Authors:
- 1 December 2008
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (12) , 1411-1419
Abstract
The impact of moderate hepatic impairment on the pharmacokinetics (PK) and pharmacodynamics (PD) of dabigatran etexilate was evaluated in an open, parallel‐group study. Healthy volunteers (n = 12) and patients with hepatic impairment (Child‐Pugh classification B; n = 12) received a single oral dose of 150 mg dabigatran etexilate. The mean values for area under the concentration‐time curve, terminal half‐life, and renal clearance of dabigatran were comparable between patients with hepatic impairment and healthy volunteers. Conversion of the dabigatran intermediate BIBR1087 to active dabigatran was slower in patients with hepatic impairment, indicating that the liver is partly involved in bioconversion of dabigatran etexilate. However, total drug exposure was comparable between groups; therefore, this observation is of no clinical relevance with respect to the anticoagulant activity of dabigatran. The extent of dabigatran glucuronidation was unchanged by liver disease; glucuronidation capacity was maintained in moderate liver disease. The activated partial thromboplastin time, ecarin clotting time, and thrombin time relationships were essentially identical in both groups. This study shows that moderate hepatic impairment does not affect the PK/PD or safety profile of dabigatran. Therefore, patients with moderate hepatic impairment can be given dabigatran etexilate without the need for dose adjustment.Keywords
This publication has 19 references indexed in Scilit:
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007
- Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialThe Lancet, 2007
- The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBritish Journal of Clinical Pharmacology, 2007
- A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJournal of Thrombosis and Haemostasis, 2005
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 2004
- The Pharmacology and Management of the Vitamin K AntagonistsChest, 2004
- Serine proteases as targets for antithrombotic therapyDrugs of the Future, 2003
- Structure-Based Design of Novel Potent Nonpeptide Thrombin InhibitorsJournal of Medicinal Chemistry, 2002
- Drug Administration in Chronic Liver DiseaseDrug Safety, 1997
- Clinical Pharmacokinetics in Patients with Liver DiseaseClinical Pharmacokinetics, 1991